Alkaptonuria

Alkaptonuria is a rare, lifelong, inherited disease of body chemistry. Your body normally breaks down the amino acids phenylalanine and tyrosine into smaller safe parts. One step of this breakdown needs an enzyme called homogentisate 1,2-dioxygenase (HGD). In alkaptonuria, the HGD enzyme does not work well because of a change (mutation) in the HGD gene you inherit from your parents. Because this step fails, a chemical called homogentisic acid (HGA) builds up in the body.

Alkaptonuria (AKU) is a rare, inherited metabolic disease. It happens when your body cannot properly break down the amino acids tyrosine and phenylalanine. A missing or weak enzyme called homogentisate 1,2-dioxygenase (HGD) causes a chemical called homogentisic acid (HGA) to build up in the body. Extra HGA slowly deposits in connective tissues (cartilage, tendons, discs, skin, eyes, heart valves). Over years this pigment turns tissues dark (called ochronosis) and makes them brittle. Typical early sign: urine that turns dark brown-black when left standing or mixed with bleach/alkali. Later in life, people often develop back stiffness, large-joint arthritis, tendon problems, kidney/prostate stones, and sometimes heart valve disease. AKU is lifelong and genetic (autosomal recessive). NCBI+2MedlinePlus+2

Extra HGA leaks into the urine and turns the urine dark brown or almost black after it stands for some time or is exposed to air or alkali (like soap). Over many years, HGA also sticks to collagen in cartilage, tendons, skin, and other tissues. The HGA becomes a dark pigment and causes “ochronosis,” which means dark discoloration of tissues. This pigment makes cartilage and other connective tissues brittle, stiff, and easy to damage. As a result, many adults with alkaptonuria develop early and painful arthritis, especially in the spine, hips, knees, and shoulders. Some people also get kidney stones, prostate stones, heart valve problems (especially aortic valve), and dark ear cartilage or bluish-grey areas of the white of the eyes.

Alkaptonuria is autosomal recessive. This means a person gets the condition only when they inherit two non-working HGD gene copies—one from each parent (the parents are usually healthy “carriers”). The disease is present from birth, but symptoms grow slowly and often appear after age 20–30, with joint problems becoming more obvious in the fourth to sixth decades of life.

Alkaptonuria is not caused by infection, and it is not contagious. It is a metabolic (biochemical) problem that affects many parts of the body because connective tissue is everywhere.

---

Other names

• AKU

• HGD deficiency (homogentisate 1,2-dioxygenase deficiency)

• Homogentisic acidemia / homogentisic aciduria

• Endogenous ochronosis due to alkaptonuria (to distinguish from acquired/exogenous ochronosis)

• Alcaptonuria (older spelling; sometimes seen in older texts)

---

Types

Doctors often describe “types” of alkaptonuria by how and where the disease shows itself over time. These are not different diseases, but different patterns or stages in the same condition.

1. Biochemical-only type (infant/childhood phase). The only sign is urine that darkens on standing; the child feels normal otherwise.

2. Early pigment type (teens/young adult). Scleral spots (small bluish-grey patches on the whites of the eyes) or ear cartilage darkening may appear, but there is little pain.

3. Musculoskeletal-dominant type (common adult type). Back pain, hip/knee/shoulder arthritis, stiffness, and reduced movement are the main problems.

4. Spine-dominant type. The lumbar and thoracic spine become stiff early, with reduced flexibility and sometimes a hunched posture.

5. Cardio-valvular type. The dark pigment builds in heart valves (especially the aortic valve), causing thickening and possible aortic stenosis in later adult life.

6. Renal/urologic type. Kidney stones and prostate stones (in men) cause flank pain, blood in urine, or urinary blockage.

7. Tendon and soft-tissue type. Painful Achilles tendon, rotator cuff problems, or meniscal wear occur because pigment makes tissues brittle.

8. Severe early-onset phenotype. Rare families with two very strong (null) mutations may show earlier and faster joint damage.

9. Mild/late-onset phenotype. People with less severe (hypomorphic) mutations may have later and milder joint problems.

(Again, these are patterns on a spectrum, not strict categories.)

---

Causes

Important note: There is one true cause of alkaptonuria: pathogenic mutations in the HGD gene that make the HGD enzyme fail. Many other things do not cause alkaptonuria, but they can modify how severe the disease becomes or trigger symptoms earlier. Below, Cause 1 is the real cause. Causes 2–20 are modifiers or risk factors that may worsen disease expression or speed up problems. I list them separately so you have a full picture.

1. Biallelic HGD gene mutations (true cause). Inheriting two faulty HGD copies stops proper breakdown of homogentisic acid. HGA builds up in urine and tissues (ochronosis).

2. Autosomal recessive inheritance pattern. Having carrier parents increases the chance a child will inherit two faulty copies.

3. Consanguinity (parents related by blood). This increases the chance both parents carry the same HGD mutation.

4. Founder effect in certain populations. Some regions have a higher frequency of specific HGD mutations due to historical population patterns.

5. High lifetime load of phenylalanine/tyrosine. Diets very high in these amino acids may raise HGA production, though diet alone cannot cause AKU.

6. Aging. Time allows more HGA to deposit and oxidize, so symptoms worsen with age.

7. High mechanical joint stress. Heavy labor, repetitive impact sports, or obesity increase wear on pigment-stiffened cartilage.

8. Smoking and oxidative stress. Oxidative stress may promote HGA oxidation and pigment formation in tissues.

9. Chronic low-grade inflammation. Inflammation can damage cartilage already made fragile by pigment.

10. Poor muscle support / weakness. Weak muscles around joints increase joint load and speed degeneration.

11. Obesity. Extra body weight increases stress on hips, knees, and spine.

12. Diabetes or metabolic syndrome. These conditions may worsen cartilage health and healing.

13. Vitamin C deficiency or low antioxidant intake. Antioxidants may help reduce oxidation of HGA; deficiency might allow more pigment formation (evidence is mixed).

14. Dehydration and low urine flow. Can favor stone formation in kidneys and prostate.

15. Recurrent urinary infections. May promote stone growth and urinary symptoms.

16. Hard water / high mineral intake. More urinary minerals can contribute to stone risk (not a cause of AKU itself).

17. Sedentary lifestyle. Poor joint mobility and weak muscles accelerate stiffness and pain.

18. Occupational vibration/strain. Long-term vibration or awkward postures stress joints/discs.

19. Coexisting spine problems. Disc disease or scoliosis can compound pain and disability in AKU.

20. Late diagnosis and lack of supportive care. Without guidance, people may overload joints or miss early heart/stone checks, making outcomes worse.

---

Symptoms

1. Urine that turns dark on standing. Fresh urine may look normal, but after minutes to hours it becomes brown or almost black due to HGA oxidation, especially if the urine touches air or soap.

2. Dark ear cartilage. The outer ear can slowly turn blue-black or slate colored. It is usually painless but a key clue.

3. Scleral pigmentation. Small bluish-grey spots appear on the whites of the eyes near the cornea (often at 3 and 9 o’clock). Vision is usually normal.

4. Dark skin patches in sweat or on sun-exposed areas. Bluish-brown areas can appear on cheeks, forehead, or where sweat collects (armpits), and on scars.

5. Low back pain and stiffness. The spine is often the first painful site, with morning stiffness and reduced flexibility.

6. Hip and knee pain. Weight-bearing joints become stiff, swollen, and painful, often beginning by the 30s–40s.

7. Shoulder and hand problems. Shoulder impingement or grip pain can occur due to tendon and cartilage changes.

8. Crepitus (grating) and reduced range of motion. Joints may crunch with movement and do not move as far as before.

9. Posture changes. Some people develop a bent or stooped posture from stiff spinal discs and facet joints.

10. Tendon pain or rupture. The Achilles tendon and rotator cuff are more brittle and can tear.

11. Kidney stones. Flank pain, blood in urine, and urinary urgency may occur due to stones.

12. Prostate stones and urinary obstruction (men). Trouble starting urine, weak stream, or frequent urination can appear.

13. Heart valve problems. Shortness of breath, chest discomfort, or fainting on exertion may occur later from aortic valve narrowing.

14. Dark earwax and sweat stains. Earwax can look dark brown; clothing may show brownish sweat stains.

15. Fatigue and reduced activity. Chronic pain and stiffness limit exercise, leading to deconditioning and tiredness.

---

Diagnostic tests

A) Physical examination (bedside observations)

1. Urine-darkening observation. The clinician may ask you to collect fresh urine and watch it darken on standing or when alkali is added; this supports the diagnosis.

2. Skin and ear inspection. Doctor looks for bluish-black ear cartilage, dark earwax, and bluish-brown skin patches on cheeks, armpits, hands, and old scars.

3. Eye examination (slit lamp if available). Small grey-blue scleral spots near the cornea are typical and do not affect vision.

4. Spine flexibility check. The clinician checks forward bending, side bending, and rotation, often finding reduced range and pain.

5. Large-joint exam. Hips, knees, and shoulders are checked for swelling, warmth, tenderness, crepitus, and movement limits.

B) Manual musculoskeletal tests (hands-on maneuvers)

6. Schober test (lumbar flexion). Measures how much the lower back can bend forward; reduced expansion suggests spinal stiffness from pigment-damaged discs.

7. FABER/Patrick test (hip). Hip is positioned in flexion-abduction-external rotation; groin pain suggests hip joint involvement.

8. Apley grind or McMurray maneuvers (knee). These tests help detect meniscal wear or cartilage roughness common in ochronotic knees.

9. Shoulder impingement tests (e.g., Neer, Hawkins). Pain with these maneuvers suggests rotator cuff irritation due to brittle, pigmented tissues.

10. Gait and functional tests (sit-to-stand, timed walk). These simple tests show real-life impact of stiffness and pain on function.

C) Laboratory and pathological tests

11. Urinary homogentisic acid (HGA) quantification. The key biochemical test. High HGA in urine confirms HGD pathway block.

12. Ferric chloride test (historical quick test). Adding ferric chloride to urine may cause a dark color change in samples with high HGA (supportive, not definitive).

13. Gas chromatography–mass spectrometry (GC-MS) or LC-MS/MS. Precise lab methods to identify and measure HGA and related metabolites.

14. Plasma/urine organic acid profile. Helps exclude other metabolic disorders and supports the pattern typical of AKU.

15. Genetic testing of the HGD gene. Finds two pathogenic variants, confirming the molecular diagnosis and allowing family testing.

16. Enzyme activity (research/rarely clinical). Measuring HGD activity in cultured cells can show reduced or absent function (used mainly in research).

17. Cartilage or tissue histology (if surgery occurs). Removed cartilage shows ochronotic pigment: dark deposits with brittle, degenerated collagen on microscopy.

18. Renal function and urinalysis. Checks for blood, crystals, infection, and kidney function, since stones and obstruction can occur.

D) Electro-diagnostic / physiologic tests

19. Electrocardiogram (ECG). Looks for heart strain or rhythm issues that can happen in people with aortic valve disease from pigment deposits. It does not diagnose AKU directly, but it monitors heart impact.

20. Treadmill exercise test or Holter (selected cases). If there are exertional symptoms, these tests help assess heart function and rhythm while planning valve care.
    (Note: Strict nerve conduction studies are not routine for AKU, but may be used if joint changes cause nerve entrapment symptoms.)

E) Imaging tests (often crucial for complications)

21. Spine X-rays. Show disc space narrowing, calcified intervertebral discs, and bone spurs typical of ochronotic spondylosis.

22. Hip and knee X-rays. Reveal joint space loss, osteophytes, and sometimes calcified cartilage earlier than expected for age.

23. Shoulder X-ray or MRI. Looks for rotator cuff tears, calcific deposits, and joint degeneration.

24. Echocardiography (heart ultrasound). Checks aortic valve thickening or narrowing and other valve problems linked to pigment deposition.

25. Renal and urinary tract ultrasound. Finds kidney stones and checks for hydronephrosis (back-pressure from blockage).

26. CT urogram (selected cases). Gives a detailed picture of urinary stones and anatomy if ultrasound is unclear.

27. MRI of spine. Shows disc degeneration, end-plate changes, and soft-tissue involvement without radiation exposure.

28. DEXA scan (if needed). Not specific for AKU but evaluates bone density, since inactivity and chronic pain can lead to bone loss.

29. Plain photos under standardized light. Serial clinical photos of ear cartilage, sclera, and skin patches help track pigment over time.

30. Dental/temporomandibular joint imaging (if symptomatic). Some patients develop jaw joint discomfort; imaging can guide care.

Non-pharmacological (non-drug) treatments

(each with description, purpose, and mechanism)

1. Education and lifelong monitoring
   Description: Learn AKU basics, triggers, and complications; keep scheduled check-ups (joints, kidneys, heart, eyes).
   Purpose: Catch problems early and slow damage.
   Mechanism: Timely surveillance (urinalysis/stone checks, heart valve echoes, eye exams) leads to earlier supportive care and fewer late complications. NCBI

2. Tyrosine/phenylalanine-controlled diet (especially if on nitisinone)
   Description: Moderately limit protein sources rich in tyrosine/phenylalanine; use dietitian guidance.
   Purpose: Keep blood tyrosine in the safe range and support therapy.
   Mechanism: With nitisinone, tyrosine levels rise; dietary control helps prevent corneal crystals and other side effects. PubMed+2Karger+2

3. Adequate hydration
   Description: Aim for clear-to-pale urine unless contraindicated.
   Purpose: Reduce kidney/prostate stone risk.
   Mechanism: Higher urine volume lowers stone-forming concentration. MedlinePlus

4. Weight management
   Description: Keep a healthy body weight.
   Purpose: Reduce load on hips, knees, and spine.
   Mechanism: Less mechanical stress slows joint wear in ochronotic cartilage.

5. Low-impact aerobic exercise
   Description: Walking, cycling, swimming.
   Purpose: Preserve joint motion and heart-lung fitness.
   Mechanism: Improves muscle support around joints without high impact.

6. Targeted physiotherapy
   Description: Range-of-motion, stretching, and core/back-stabilizing programs.
   Purpose: Maintain flexibility; reduce stiffness and pain.
   Mechanism: Keeps ochronotic tissues mobile, supports degenerated discs and joints.

7. Strength training (joint-friendly)
   Description: Light resistance for hips, knees, shoulders, and back.
   Purpose: Support unstable joints.
   Mechanism: Strong muscles offload stressed cartilage.

8. Posture and ergonomics
   Description: Spine-safe sitting, standing, and lifting; ergonomic chairs and supports.
   Purpose: Decrease back stress.
   Mechanism: Limits repeated micro-trauma to degenerating discs.

9. Assistive devices when needed
   Description: Orthotics, cushioned shoes, canes, braces, raised toilet seats.
   Purpose: Pain relief and safer mobility.
   Mechanism: Offloads joints and improves balance.

10. Heat and cold therapy
    Description: Warm showers/heat packs before activity; ice after flares.
    Purpose: Ease stiffness and reduce inflammation.
    Mechanism: Heat relaxes soft tissues; cold lowers local blood flow and swelling.

11. Occupational therapy (activity modification)
    Description: Redesign tasks to reduce force and repetition.
    Purpose: Keep independence at work/home.
    Mechanism: Minimizes cumulative joint strain.

12. Fall-prevention measures
    Description: Home safety checks, balance training.
    Purpose: Prevent injuries in stiff joints.
    Mechanism: Addresses instability from ochronotic arthropathy.

13. Sleep optimization and pacing
    Description: Regular sleep times; break large chores into smaller ones.
    Purpose: Pain coping and energy conservation.
    Mechanism: Lowers central sensitization and fatigue.

14. CBT/mind-body pain skills
    Description: Cognitive behavioral therapy, relaxation, breathing.
    Purpose: Improve pain control and mood.
    Mechanism: Modifies pain perception pathways.

15. Sun/eye care if on nitisinone with high tyrosine
    Description: Prompt eye assessments if vision discomfort; sunglasses/lubricants as advised.
    Purpose: Reduce risk of corneal problems.
    Mechanism: High tyrosine can cause corneal crystals; proactive eye care helps. PubMed

16. Stone prevention strategies
    Description: Diet advice for stones (e.g., urine alkalinization guidance from clinicians).
    Purpose: Lower new stone formation.
    Mechanism: Appropriate urine chemistry reduces precipitation. MedlinePlus

17. Cardiovascular risk reduction
    Description: Control blood pressure, lipids; don’t smoke.
    Purpose: Support heart/valve health in later life.
    Mechanism: Reduces added stress on potentially calcifying valves. NCBI

18. Regular dental and ear-skin checks
    Description: Look for pigmentation and tissue fragility.
    Purpose: Early recognition of ochronosis sites.
    Mechanism: Guides protective practices. NCBI

19. Orthopedic care pathways
    Description: Early referral for joint injections or surgical planning when function drops.
    Purpose: Maintain mobility and independence.
    Mechanism: Timely interventions limit disability progression. NCBI

20. Genetic counseling for families
    Description: Discuss inheritance and testing options.
    Purpose: Informs family planning.
    Mechanism: Explains autosomal recessive risk and carrier testing. MedlinePlus

---

Drug treatments

Important: Only one medicine specifically lowers HGA production—nitisinone. All others are for symptoms or complications. Always use the lowest effective dose and follow your clinician’s plan.

1. Nitisinone (NTBC, Orfadin®)
   Class: 4-hydroxyphenylpyruvate dioxygenase inhibitor.
   Typical adult dose/time: Common research/clinical doses 2–10 mg once daily; centers individualize based on HGA/tyrosine levels. (Some reports show HGA reduction even at very low doses; dosing must be supervised).
   Purpose: Disease-modifying: lowers HGA production.
   Mechanism: Blocks a step upstream of HGA, reducing HGA by >95% in many patients; improves biochemical markers and may slow tissue damage.
   Key side effects: Tyrosinemia with risk of corneal crystals/keratopathy, dry eyes/photophobia, skin symptoms; requires diet control and monitoring of plasma tyrosine.
   Evidence & status: In 2020 the EMA approved Orfadin® for adults with AKU; trials (SONIA-1/2) and real-world data show large HGA reductions and clinical benefits, with diet needed to manage tyrosine. PubMed+4European Commission+4European Medicines Agency (EMA)+4

2. Acetaminophen (paracetamol)
   Class: Analgesic/antipyretic.
   Dose/time: 500–1000 mg up to every 6–8 h (max per local guidance).
   Purpose: Baseline pain relief.
   Mechanism: Central COX inhibition.
   Side effects: Liver toxicity at high doses.

3. NSAIDs (e.g., ibuprofen, naproxen)
   Class: Non-steroidal anti-inflammatory drugs.
   Dose/time: Ibuprofen 200–400 mg q6–8h; naproxen 250–500 mg q12h (per label).
   Purpose: Reduce joint pain and stiffness.
   Mechanism: COX inhibition lowers prostaglandins.
   Side effects: Stomach ulcers, kidney effects, BP rise; use gastroprotection if needed.

4. COX-2 inhibitor (celecoxib)
   Class: Selective NSAID.
   Dose/time: 100–200 mg once/twice daily.
   Purpose: Arthritis pain with less GI risk (not zero).
   Mechanism: COX-2 selective blockade.
   Side effects: Cardiovascular risk; kidney effects.

5. Topical NSAIDs (diclofenac gel)
   Class: Topical anti-inflammatory.
   Dose/time: Applied to painful joints 3–4×/day.
   Purpose: Local pain relief with fewer systemic effects.
   Mechanism: Local COX inhibition.
   Side effects: Skin irritation.

6. Intra-articular corticosteroids
   Class: Glucocorticoids.
   Dose/time: Per joint, episodic.
   Purpose: Short-term relief in inflamed joints.
   Mechanism: Anti-inflammatory gene modulation.
   Side effects: Flare, infection risk (rare), cartilage effects with frequent use.

7. Duloxetine
   Class: SNRI.
   Dose/time: 30–60 mg daily.
   Purpose: Chronic musculoskeletal pain modulation.
   Mechanism: Central pain pathway modulation.
   Side effects: Nausea, sleep changes, BP effects.

8. Tramadol (short course, if needed)
   Class: Atypical opioid.
   Dose/time: 25–50 mg q6h PRN (lowest effective dose).
   Purpose: Breakthrough pain not controlled by NSAIDs/acetaminophen.
   Mechanism: μ-opioid + SNRI activity.
   Side effects: Nausea, dizziness, dependence risk; avoid long-term use.

9. Gabapentin/pregabalin
   Class: Neuropathic pain modulators.
   Dose/time: Titrated.
   Purpose: Nerve-type pain from spine degeneration.
   Mechanism: α2δ subunit modulation of calcium channels.
   Side effects: Sedation, edema.

10. Proton pump inhibitor (omeprazole) when needed
    Class: Acid suppression.
    Dose/time: 20 mg daily.
    Purpose: Protect stomach in NSAID users at risk.
    Mechanism: Blocks gastric H+/K+ ATPase.
    Side effects: Long-term nutrient effects; use only when indicated.

11. Topical capsaicin
    Class: TRPV1 agonist.
    Dose/time: 0.025–0.1% cream 3–4×/day.
    Purpose: Reduce localized joint pain.
    Mechanism: Depletes substance P.
    Side effects: Burning; wash hands.

12. Hyaluronic acid injections (selected joints)
    Class: Viscosupplement.
    Dose/time: Per protocol.
    Purpose: Lubrication for knee OA-type pain.
    Mechanism: Improves synovial viscosity.
    Side effects: Local swelling; variable benefit.

13. Potassium citrate / urine alkalinization (if prescribed)
    Class: Urinary alkalinizer.
    Dose/time: Individualized.
    Purpose: Prevent some kidney stones.
    Mechanism: Raises urinary pH and citrate.
    Side effects: GI upset; monitor electrolytes. MedlinePlus

14. Alpha-blocker (tamsulosin) for stone passage (when indicated)
    Class: Uroselective α1-blocker.
    Dose/time: 0.4 mg nightly short course.
    Purpose: Help pass ureteral stones.
    Mechanism: Relaxes ureteral smooth muscle.
    Side effects: Dizziness, low BP.

15. Lubricating eye drops (if corneal irritation/tyrosine crystals)
    Class: Artificial tears.
    Dose/time: PRN.
    Purpose: Soothe symptoms; protect surface.
    Mechanism: Tear film support.
    Side effects: Minimal. PubMed

16. Antibiotics only for confirmed infections
    Class: As per culture/site.
    Purpose: Treat UTIs after stones or post-op infections.
    Mechanism: Pathogen-specific.
    Side effects: Drug-specific.

17. Bisphosphonates (selected patients with osteoporosis)
    Class: Anti-resorptive.
    Dose/time: Per osteoporosis protocols.
    Purpose: Bone protection if low bone density.
    Mechanism: Inhibits osteoclasts.
    Side effects: GI irritation, rare ONJ.

18. Topical lidocaine patches
    Class: Local anesthetic.
    Dose/time: Up to 12 h/day.
    Purpose: Focal pain relief.
    Mechanism: Sodium channel blockade.
    Side effects: Skin irritation.

19. Short oral steroid taper for acute inflammatory flares (selected cases)
    Class: Glucocorticoid.
    Purpose: Temporarily calm severe inflammation.
    Mechanism: Anti-inflammatory gene effects.
    Side effects: Glucose rise, mood, BP—avoid frequent use.

20. Vitamin C (ascorbic acid) – limited, uncertain benefit
    Class: Antioxidant.
    Dose/time: Historical regimens 250–1000 mg/day were used.
    Purpose: Theoretical reduction of HGA oxidation; evidence weak.
    Mechanism: Antioxidant action may reduce pigment formation but has not shown strong clinical benefit.
    Side effects: GI upset, kidney stone risk in high doses. Wiley Online Library

---

Dietary molecular supplements

Always discuss supplements with your clinician—some interact with medicines or stones.

1. Vitamin C (see above) – 250–500 mg/day if used; antioxidant; may reduce HGA oxidation (evidence limited). Wiley Online Library

2. Omega-3 fatty acids – 1–2 g/day EPA+DHA; anti-inflammatory; membrane mediator competition.

3. Vitamin D3 – individualized to maintain normal levels; bone health; supports calcium homeostasis.

4. Calcium (diet first) – only if low intake; bone support; mineralization.

5. Magnesium – 200–400 mg/day if low; muscle/nerve function; may help certain stone profiles.

6. Turmeric/curcumin – standardized extract as advised; anti-inflammatory signaling; use cautiously with anticoagulants.

7. Glucosamine/chondroitin – trial for OA-type symptoms; cartilage matrix support (benefit varies).

8. Collagen peptides – 5–10 g/day; joint comfort in some trials; provides amino acids for matrix.

9. Probiotics/fiber – daily; gut health; may aid NSAID tolerance and overall well-being.

10. Citrate (dietary sources like citrus; supplements only if prescribed) – supports urinary citrate; may help reduce stone risk when appropriate. MedlinePlus

---

Immunity booster / regenerative / stem-cell” drug

Clear note: There are no approved immune-booster or stem-cell drugs for AKU. The items below are investigational concepts only—not standard care. Use clinical trials only; no over-the-counter “immunity boosters” repair ochronosis.

1. Gene therapy targeting HGD – Goal: restore the missing enzyme in liver; status: preclinical/early research; no clinical dose established.

2. mRNA or gene-editing (CRISPR) approaches – Goal: correct HGD mutation; status: experimental only; no approved regimen.

3. Cell-based cartilage repair (MSC chondroprogenitors) – Goal: patch focal joint damage; status: investigational; dose/protocols vary in trials.

4. Tissue-engineered discs/cartilage scaffolds – Goal: replace degenerated tissue; status: research setting only.

5. Small-molecule HGD chaperones – Goal: stabilize mutant HGD; status: theoretical/early discovery.

6. Very-low-dose nitisinone “preventive” strategy – Some research explores micro-dosing to limit tyrosinemia while suppressing HGA; use only under expert supervision within protocols. BioMed Central

---

Surgeries

1. Total hip arthroplasty (hip replacement)
   Why: End-stage ochronotic hip arthritis causing severe pain and disability.
   What happens: Damaged joint surfaces are replaced with implants to relieve pain and improve motion.

2. Total knee arthroplasty (knee replacement)
   Why: End-stage ochronotic knee arthritis.
   What happens: Resurfaces femur/tibia with prosthetic components to restore function.

3. Spine surgery (decompression/fusion, selected cases)
   Why: Severe spinal stenosis, nerve compression, or instability from disc degeneration/ochronosis.
   What happens: Removes pressure on nerves ± stabilizes segments.

4. Aortic (or mitral) valve replacement
   Why: Calcified or dysfunctional valve due to ochronosis leading to heart failure or symptoms.
   What happens: Diseased valve replaced via open or transcatheter technique. NCBI

5. Stone surgery (URS/ESWL/PCNL as indicated)
   Why: Kidney/ureter/prostate stones causing pain, blockage, or infection.
   What happens: Fragmentation or removal with endoscopic or percutaneous methods. MedlinePlus

---

Prevention strategies

You cannot “prevent” being born with AKU, but you can prevent or delay many complications.

1. Genetic counseling and informed family planning (carrier testing where available). MedlinePlus

2. Early diagnosis and regular specialist follow-up (metabolic, orthopedic, renal, cardiology, ophthalmology). NCBI

3. Discuss nitisinone early with an expert center to reduce HGA burden; ensure dietary support to manage tyrosine. European Medicines Agency (EMA)+1

4. Protein moderation/quality (especially on nitisinone) to keep tyrosine in range. akusociety.org

5. Hydration to lower stone risk. MedlinePlus

6. Joint-friendly lifestyle (low impact exercise, avoid high-impact sports).

7. Maintain healthy weight to reduce joint load.

8. Ergonomics/posture to protect spine and large joints.

9. Manage blood pressure/lipids; don’t smoke to support heart/valve health. NCBI

10. Prompt treatment of UTIs and stones to avoid complications. MedlinePlus

---

When to see a doctor

• Immediately if you have severe back/hip/knee pain that stops you walking, fever with kidney stone pain, blood in urine, sudden vision pain/sensitivity to light (possible corneal issue), chest pain, fainting, or shortness of breath.

• Soon if urine turns dark, you notice new bluish-black spots on ears/eyes, your joints are getting stiffer, you pass stones, or you have morning back stiffness that is worsening.

• Regularly for planned follow-ups: metabolic team (AKU specialist), dietitian (especially with nitisinone), kidney/stone checks, spine/joint review, heart valve echocardiograms when advised, and eye exams—more often if on nitisinone. NCBI+1

---

Diet: eat this” and limit/avoid

Eat (focus on balance and moderation, especially if on nitisinone):

1. Plenty of water spread through the day (if your doctor agrees). MedlinePlus

2. Colorful fruits and vegetables (fiber, antioxidants).

3. Whole grains (oats, brown rice) for steady energy.

4. Healthy fats (olive oil, nuts in sensible portions).

5. Dairy or fortified alternatives to meet calcium/vitamin D needs (per dietitian).

6. Lean, measured protein portions (dietitian-planned to manage tyrosine/phenylalanine). PubMed

7. Citrus and other citrate-rich foods if appropriate for stone prevention. MedlinePlus

8. High-fiber foods to support gut health, especially if using pain meds.

9. Spices like ginger/garlic for flavor instead of excess salt.

10. Dietitian-approved medical foods if prescribed to control tyrosine/phenylalanine. Karger

Limit/avoid (especially on nitisinone):

1. Very high-protein portions (large red-meat servings). PubMed

2. Protein isolates and bodybuilding shakes not approved by your team.

3. Aged cheeses and processed meats (dense protein; salt).

4. Soy protein concentrates/gelatin (often high in tyrosine/phenylalanine).

5. Ultra-processed snacks high in salt/sugar.

6. Excess vitamin C supplements beyond clinician advice (stone risk). Wiley Online Library

7. Very low-carb, very high-protein fad diets.

8. Sugary drinks (weight and metabolic health).

9. Alcohol excess (liver, balance, injury risk).

10. Any supplement promising to “cure” AKU—not evidence-based.

---

Frequently asked questions (FAQs)

1) Is alkaptonuria curable?
Not yet. It is genetic and lifelong. But nitisinone can dramatically lower HGA, and good care can delay or reduce complications. European Medicines Agency (EMA)+1

2) How is AKU diagnosed?
By finding high HGA in urine/plasma and/or HGD gene variants by genetic testing. Doctors also look for dark urine and ochronosis signs. NCBI+1

3) What age do symptoms start?
Urine darkening can show in infancy, but joint and tissue changes usually appear in adulthood (often 30s+). NCBI

4) Does everyone with AKU need nitisinone?
Discuss with a specialist. Many adults benefit biochemically; treatment is individualized, balancing HGA reduction with tyrosine management and eye safety. PMC+1

5) What tests are needed during follow-up?
Urine/plasma HGA and tyrosine (if on nitisinone), kidney/stone checks, musculoskeletal review, and periodic echocardiogram and eye exams. NCBI

6) Why does my urine turn black?
When HGA in urine meets air/alkali it oxidizes and darkens. NCBI

7) What is ochronosis?
Dark pigment from oxidized HGA collects in connective tissue, turning cartilage and other tissues bluish-black and making them brittle. NCBI

8) Can diet alone treat AKU?
Diet helps more when you are on nitisinone (to control tyrosine). Diet alone has limited evidence for slowing disease without medication, but healthy eating supports joints and stone prevention. PMC+1

9) What eye issues can happen on nitisinone?
High tyrosine may cause corneal crystals leading to light sensitivity or discomfort. Diet and monitoring help keep levels safe. Report eye symptoms promptly. PubMed

10) Are there special risks in pregnancy?
Discuss plans early with your metabolic team. Medication and diet choices need individualized risk-benefit review.

11) Will I definitely need joint replacements?
Not everyone, but many will need major joint surgery over time. Good rehab, weight control, and timely care can delay it. NCBI

12) Why do some people get heart valve problems?
Pigment can deposit and contribute to calcification, especially in the aortic valve, over decades. Monitoring finds trouble early. NCBI

13) Are there clinical trials?
Trials have tested nitisinone and are exploring dosing and diet strategies; future studies may evaluate gene and cell therapies. Ask an AKU center about current options. PMC+1

14) Can children be treated?
Management is individualized. Nitisinone’s EMA approval is for adults with AKU; pediatric use requires expert, case-by-case consideration and careful monitoring. European Medicines Agency (EMA)

15) Where can I learn more and get diet help?
Look for specialist metabolic centers and reputable patient groups with diet resources specifically for AKU and nitisinone users. akusociety.org

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 12, 2025.